LONDON – Amiko Digital Health Limited, a company that develops advanced medication sensor technologies and artificial intelligence-powered digital health tools, has received CE Mark for use of the Respiro platform with Teva’s Spiromax inhaler, Chiesi’s Nexthaler inhaler and GlaxoSmithKline’s Ellipta inhaler. “Receiving the CE Mark is a significant milestone toward the global commercialization of our connected inhaler technology,” said Federica Iovine, director of regulatory affairs at Amiko, in a statement. Respiro offers advanced inhaler sensors and connected health tools, enabling real-time monitoring of medication use and patient health. Combined with inhalers for asthma, chronic obstructive pulmonary disease and cystic fibrosis, the sensors automatically capture data on the patient’s inhalation profiles to monitor when and how well patients use their medication.
CAMBRIDGE, England – Respiratory solutions provider GSK will incorporate a breath biopsy platform from Owlstone Medical into the development of a drug in its respiratory disease pipeline. Owlstone Medical’s Breath Biopsy platform analyzes biomarkers from breath and has the potential to generate data needed to improve clinical outcomes and reduce health care costs. “We believe that the non-invasive Breath Biopsy can rapidly establish a central role in a variety of precision medicine applications such as patient stratification and monitoring treatment response,” said Billy Boyle, co-founder and CEO at Owlstone Medical, in a statement. “We intend to work with multiple pharmaceutical partners looking to optimize the health economic impact of their new medicines across a broad range of diseases by providing access to the data needed to ensure that the right therapy is given to the right patient at the right time.” GSK will use the platform as part of a Phase II clinical trial to assess whether the right patient for the right treatment can be identified, as well as to assess the treatment effects of a novel drug for chronic obstructive pulmonary disease.
MADISON, Wis. –Propeller Health has extended its collaboration with respiratory medicine provider GSK.
The two companies began working together in 2015 to research and collect evidence from Propeller’s clip-on sensor and software platform used in conjunction with GSK’s ELLIPTA inhaler and respiratory medicines for asthma and COPD.
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the U.S.,” said David Van Sickle, CEO and co-founder of Propeller, in a statement.
The clip-on sensor for the ELLIPTA Inhaler automatically records medication use, which the Propeller platform analyzes and presents to patients and physicians through its data-driven digital interfaces, providing an in-depth view into adherence.
The Propeller sensor and software program for the ELLIPTA Inhaler received CE marking and clearance from the U.S. Food and Drug Administration last year.
“Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition,” said Eric Dube, senior vice president and head of GSK, in a statement.
AMSTERDAM – Royal Philips has signed an agreement to acquire Respiratory Technologies, Inc. (RespirTech), a provider of an airway clearance vest for patients with chronic respiratory conditions, such as chronic obstructive pulmonary disease and cystic fibrosis. The expansion of Philips’ respiratory care portfolio with RespirTech’s vest therapy solution and robust clinical support program for in-home respiratory care will further strengthen Philips’ solutions to manage care at home, said John Frank, Philips’ business leader, Sleep & Respiratory Care, in a statement. “With this transaction, we will broaden our portfolio with a proven therapy to enable patients with chronic respiratory disorders to manage their condition and receive the care they need in the home,” he said. “By helping these patients help themselves, we aim to enhance the patient’s quality of life and reduce the overall cost of care.” RespirTech was founded in 2004 and is headquartered in St. Paul, Minn. The company employs approximately 210 employees.
AMSTERDAM – Use of a Royal Philips noninvasive ventilation (NIV) device at home can save millions in readmission costs and reduced hospitalization rates for patients with severe chronic obstructive pulmonary disease (COPD), a recent study has found.
The Philips-sponsored study assessed whether a comprehensive strategy of care, including the use of the Philips Trilogy 100 NIV, can reduce the economic burden of managing patients with moderate to severe COPD.
“The study shows that there are actually significant economic advantages to continuing care at home for patients who require frequent hospitalizations for COPD exacerbations,” said Dr. Teofilo Lee-Chiong, chief medical liaison at Philips. “Hospital admissions and readmissions for worsening COPD account for a large portion of health care expenditure. The latter affects the patients, hospitals and payers alike.”
Conducted at Barnes Healthcare Services, the study’s at-home program of care included advanced NIV therapy with the Trilogy, oxygen therapy, respiratory therapist-led care, patient education and medication reconciliation. It found that the reduction in readmissions led to a cumulative hospital savings of more than $400,000 over 30 days. After examining 1,000 COPD patients being treated with the combined treatment method, hospitals saved $1.6 million in the first 30 days, compared to no NIV treatment or less advanced NIV therapy devices. Payers had a cumulative 3-year savings of $326 million when using home NIV in comparison to no NIV treatment.
Lee-Chiong said NIV assists patients with breathing by providing a prescribed volume of air during inspiration. Newer technologies, like the Philips Trilogy, continuously adjust the delivered pressure to reach clinically desired targets and synchronize with the patient’s patterns of breathing.
The NIV model used in the study can be easily adopted by other health care providers, facilities and payers, said Lee-Chiong.
“As health systems continue to promote value-based care, it is increasingly important to demonstrate that programs like these can reduce costs while improving patient experiences,” he said.
MINNEAPOLIS – Connected health solutions provider HealthFactors and Koronis Biomedical Technologies have announced a collaboration to improve health care and outcomes for people with respiratory conditions associated with asthma, COPD and cystic fibrosis. The companies will work on developing products and initiatives including algorithms that are used in smart inhalers. “Breakthrough treatments for complex medical conditions are being driven by a marriage of leading-edge electronic and software technology and advanced algorithms that deliver information from devices to patients, health providers, families and caregivers,” said Patrick Lichter, co-founder, president and chief technology officer of KBT, in a statement. “This type of digital solution surrounds the patient and creates a truly connected experience that factors in all aspects of their lives and health care journey.” Throughout the collaboration, HealthFactors and KBT will partner with device manufacturers, pharmaceutical companies, researchers and clinicians who are focused on emerging treatments and therapies for respiratory and other complex medical conditions.
MINNEAPOLIS, Minn. – HealthFactors and Koronis Biomedical Technologies will work together on a variety of products and initiatives to improve health care and outcomes for people living with respiratory conditions associated with asthma, COPD and cystic fibrosis. “Our collaboration with KBT blends decades of expertise in technology, engineering, research, health care delivery and pharmaceuticals to deliver patient-centered solutions,” said Dan Spors, chief commercial officer of HealthFactors, in a statement. The collaboration will include the development of algorithms that are used in smart inhalers, and several clinical and technology advancements needed for the implementation of these inhalers into mainstream clinical practice. “Breakthrough treatments for complex medical conditions are being driven by a marriage of leading-edge electronic and software technology and advanced algorithms that deliver information from devices to patients, health care providers, families and caregivers,” said Patrick Lichter, president, co-founder and chief technology officer at KBT, in a statement.
NEW YORK – Digital health company Cohero Health will use $10.5 million in Series A funding to expand its BreatheSmart respiratory disease management platform. The platform connects to the company’s smartphone-connected spirometer, which measures lung function, tracks inhaler use and gives medication reminders. The funding will support broader commercialization of the hardware and software of the platform, said Melissa Manice, co-founder and CEO of Cohero Health, in a statement.
AMSTERDAM, the Netherlands – Royal Philips has expanded its Dream Family of products with the DreamStation Advanced Therapies BiPAP autoSV and AVAPS devices to provide care for patients with complex ventilation needs. The devices are currently available in select markets in the U.S., France and Australia, and will be available globally by the end of this year. They aim to deliver optimal ventilation with minimal intervention so patients experience comfortable, restful sleep and quality of life. The DreamStation Advanced Therapies devices are fully integrated through the Philips Encore Anywhere patient management tool, providing automated support for the patient’s changing needs, as well as remote monitoring capabilities support for physicians, HME providers and caretakers to intervene when needed to minimalize adverse effects. The Dream Family of products launched in 2015 as a full suite of sleep solutions that connect and support the patient, clinician and homecare provider to enhance patient care and quality of life.
NEW YORK – Cohero Health’s pediatric medication adherence pilot with Mount Sinai Health System is just the most recent of several partnerships for the company, as it continues to experience tremendous growth in the respiratory market.
The pilot with the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai will study pediatric asthma patients using Cohero’s connected devices and game-based mobile app to increase and monitor adherence to medication.
“We’ve achieved dramatic and exciting growth this year,” said Mike Marett, Cohero’s chief commercial officer.
Cohero’s connected health tools include: BreatheSmart, a mobile app that lets patients receive medication reminders, track inhaler use and measure lung function; mSpirometer, a mobile spirometer; HeroTracker, which records inhaler usage; and CoheroConnect, a platform that allows patients and caregivers to examine their respiratory health trends on a personal web dashboard.
The company has also announced a partnership with holistic health platform ImagineCare, and introduced a new metered dose inhaler with device manufacturer Presspart Group—work that is all part of Cohero’s mission to get their products into the hands of patients who need them.
“We definitely value partnerships established,” said Marett, “and we enjoy opportunities to collaborate around improving respiratory care. We’re taking our connected suite of products and applying them to the respiratory community, to disrupt and evolve the market.”
Additionally, in November, Cohero announced the completion of what it believes is the first functional connected metered dose inhaler, called the eMDI, the result of a multi-year development effort between Cohero and Presspart. The device incorporates electronics into a medication inhaler to passively track and communicate medication utilization. It incorporates a sensor to track the date and time when medication is actuated, stores that information into onboard memory, and can share it via Bluetooth.
Marett said the company is “channel agnostic,” and works collaboratively with its partners to improve the quality of life and quality of care of patients with respiratory conditions.
“Ideally we’d be outfitting all respiratory patients with the eMDI or HeroTracker and the mSpirometer,” said Marett, “empowering patients and the stakeholders that care for them with actionable insights—this is the holy grail.”